Tag: CX
The top 10 most popular Vascular Specialist stories of May 2024
In April, the most read stories from Vascular Specialist include new data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial presented at the...
Paclitaxel controversy: Yes, device restrictions did cause harm
“Unfortunately, we are doing worse for our patients today,” were the sobering thoughts of Eric Secemsky (Boston, United States) during a late-breaking presentation in...
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they...
CX 2023: Statins save lives after aortic repair regardless of dose
Statin treatment after aortic repair is associated with improved long-term survival, while dose does not matter. This was the key message from a first-to-podium...
Vascular community split over ‘death’ of traditional carotid stenting
A debate between two prominent carotid interventionists—Peter Schneider, MD, professor of vascular and endovascular surgery at University of California San Francisco in San Francisco,...
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients
A question from Manj Gohel, MD, from Cambridge University Hospitals in Cambridge, England, on what the 2023 Charing Cross (CX) International Symposium audience should...
On 45th anniversary, CX Symposium chairman credits Chicago vascular surgical tandem...
The occasion of a seminal meeting held in Chicago by former Society for Vascular Surgery (SVS) Presidents John J. Bergan, MD, and James S.T....
Artificial intelligence could make endovascular aortic repair outcomes more predictable, CX...
At the 2022 Charing Cross (CX) International Symposium (April 26–28) in London, England, Tom Carrell, MD, a vascular surgeon in Cambridge, England, and founder of...
New sirolimus data provide encouragement despite ‘potentially disappointing’ efficacy results
The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access...
CX 2022: IN.PACT AV DCB shows sustained and superior performance compared...
New randomized controlled data demonstrating the sustained and superior performance of IN.PACT AV drug-coated balloons (DCBs) compared to percutaneous transluminal angioplasty (PTA) through 36...
CX 2022: Overtreatment in venous disease: Financial incentives are ‘the elephant...
To combat the “overtreatment problem” in the appropriate care of venous disease, “a concerted, complex, multimodal effort” is required from specialists across disparate parts...
Nearly 70% of CX 2020 LIVE global aortic audience finds type...
A global audience tuned into the second session and inaugural aortic offering of CX 2020 LIVE. With registrations now well over 4,000, the pioneering virtual...
CX 2020 LIVE pioneers virtual vascular conference format in COVID-19 era
CX 2020 LIVE came to life online—despite COVID-19—using state-of-the art broadcast technology to bring together more than 1,000 vascular specialists, live, from 95 countries across...
CX 2020 LIVE: Charing Cross Symposium unveils live, interactive digital event
The Charing Cross (CX) Symposium, with its world-class faculty and unique focus on live audience participation, has announced the launch of a not-to-be missed...
Global vascular community addresses geographic disparity in COVID-19 impact and response
LONDON—Last week, the Charing Cross (CX) Symposium 2020 would have taken place in the U.K. capital. To mark the occasion virtually, experts from across...